Shrinks In Sneakers

Tag: medication mangement

  • Suicide is a tragically common outcome in schizophrenia

    🔹 Up to 50% of patients attempt suicide
    🔹 Around 10% die by suicide

    The InterSePT trial directly addressed this crisis by comparing clozapine vs olanzapine in high-risk patients—all with recent suicidal ideation or attempts. Notably, only 27% were treatment-resistant.

    ✅ Clozapine led to a 25% reduction in suicidal behaviors—a game-changer.
    📌 This led to FDA approval for clozapine in reducing suicidality in schizophrenia.

    Let’s stop thinking of clozapine only as a last resort. Sometimes, it’s exactly what’s needed—not later, but now.

  • 💊 Are Antidepressants Overprescribed in the U.S.? 🤔

    💊 Are Antidepressants Overprescribed in the U.S.? 🤔

    The question of whether antidepressants are overprescribed in the United States is complex and depends on how “overprescription” is defined.

    Arguments Suggesting Overprescription

    1. Broad Diagnostic Criteria:
      • The criteria for diagnosing conditions like major depressive disorder (MDD) can be broad, potentially leading to overdiagnosis and, consequently, overprescription.
    2. Prescribing Practices:
      • Primary care physicians write most antidepressant prescriptions, often without thorough psychiatric evaluation.
      • Some prescriptions are written for mild cases of depression or subclinical symptoms where psychotherapy or lifestyle changes might suffice.
    3. Off-Label Use:
      • Antidepressants are frequently prescribed off-label for conditions like insomnia, chronic pain, or anxiety, contributing to their high utilization.
    4. Pharmaceutical Influence:
      • Aggressive marketing by pharmaceutical companies has historically played a role in increasing antidepressant use.

    Arguments Against Overprescription

    1. Underdiagnosis and Undertreatment:
      • Despite high prescription rates, many individuals with diagnosable depression or anxiety disorders go untreated, particularly in underserved populations.
      • Stigma and access barriers often prevent people from seeking care.
    2. Increasing Mental Health Awareness:
      • Growing awareness of mental health issues may explain rising prescription rates, as more people seek help for legitimate conditions.
    3. Non-Psychiatric Indications:
      • Antidepressants are also effective for non-depressive disorders, like obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and chronic pain, which justifies some of their broader use.

    Data on Antidepressant Use

    According to surveys, about 1 in 8 Americans aged 18 and older take antidepressants, and usage is particularly high among women, especially those aged 40–59. While this might seem like a high prevalence, it may also reflect greater recognition and treatment of mental health issues.

    Key Considerations

    • Patient-Centered Care: The decision to prescribe antidepressants should be tailored to the individual, based on a comprehensive assessment of their symptoms and needs.
    • Access to Alternatives: Many individuals lack access to evidence-based non-pharmacological treatments like psychotherapy due to cost, availability, or stigma, making antidepressants a more feasible option.
    • Role of Education: Educating both prescribers and patients on appropriate use can reduce potential overprescription.
  • Clozapine: Unlocking Relief for Negative Symptoms in Schizophrenia

    Clozapine: Unlocking Relief for Negative Symptoms in Schizophrenia

    Clozapine has been studied extensively in schizophrenia, particularly for treatment-resistant cases. Its role in managing negative symptoms (e.g., apathy, alogia, anhedonia, social withdrawal) has been investigated in various randomized controlled trials (RCTs).

    RCT Evidence for Clozapine in Negative Symptoms

    1. Clozapine vs. Typical Antipsychotics
      • Several studies have shown clozapine’s superiority over first-generation antipsychotics (FGAs) like haloperidol in reducing negative symptoms.
      • Example: A landmark RCT (Kane et al., 1988) demonstrated that clozapine not only reduced positive symptoms but also had beneficial effects on negative symptoms, potentially due to its unique pharmacology (e.g., serotonin-dopamine antagonism, NMDA receptor modulation).
    2. Clozapine vs. Other Atypical Antipsychotics
      • Mixed Results: Some RCTs suggest that clozapine is more effective than other atypical antipsychotics (e.g., risperidone or olanzapine) in improving negative symptoms, while others show no significant difference.
      • A meta-analysis of head-to-head RCTs found that while clozapine had modest effects on negative symptoms, differences between it and other atypicals were small.
    3. Clozapine in Primary Negative Symptoms
      • Challenges: True primary negative symptoms (not secondary to positive symptoms, sedation, or depression) are challenging to isolate in trials.
      • Some RCTs highlight that clozapine’s effects on negative symptoms might be indirect, mediated by improvements in positive symptoms, cognitive function, or overall social functioning.
    4. Adjunctive Therapies
      • RCTs combining clozapine with adjuncts like antidepressants (e.g., fluvoxamine) or cognitive enhancers (e.g., aripiprazole, NMDA modulators) have been conducted. While adjunctive strategies show promise, the evidence remains preliminary and inconsistent.

    Potential Mechanism

    Clozapine’s effects on negative symptoms may be attributed to:

    • Serotonin-Dopamine Antagonism: Improved dopamine transmission in the mesocortical pathway.
    • Glutamatergic Modulation: Effects on NMDA and AMPA receptors.
    • Anti-inflammatory Properties: Reduced neuroinflammation may play a role in symptom improvement.
    • Sedation Reduction: Lower propensity for extrapyramidal side effects compared to FGAs.

    Limitations of Evidence

    • Heterogeneity: Most RCTs mix patients with primary and secondary negative symptoms, confounding results.
    • Measurement Challenges: The assessment of negative symptoms in trials is often subjective and prone to bias.
    • Indirect Effects: Improvements may stem from reductions in positive symptoms or cognitive enhancements rather than direct action on negative symptoms.

    Key Takeaway

    Clozapine shows some benefit for negative symptoms, particularly when compared to FGAs and in cases with secondary negative symptoms. However, its effects on primary negative symptoms are modest, and it is generally not considered the first-line choice for this domain of schizophrenia. Adjunctive approaches or newer agents might offer additional promise.

  • Split or Stick? The Real Impact of Dividing Clozapine Doses

    Split or Stick? The Real Impact of Dividing Clozapine Doses

    This post comes from a recent discussion I had with my resident about the utility of splitting clozapine doses in a recent case we had.

    The evidence on splitting clozapine into multiple daily doses primarily stems from clinical observations and smaller studies rather than extensive, randomized controlled trials (RCTs). Since clozapine has a unique pharmacodynamic and pharmacokinetic profile, standardizing an RCT on dose splitting has been challenging.

    1. Clozapine’s Half-Life and Steady-State Concentration: Clozapine has a long half-life (averaging about 12 hours), meaning steady-state concentrations can be reached without strict multiple dosing. Many patients maintain stable blood levels with once-daily dosing, especially at lower doses.
    2. Dose Splitting and Side Effects: Some smaller studies and clinical observations suggest that splitting doses can help reduce peak plasma levels of clozapine, which can be associated with side effects like sedation, hypotension, and dizziness. In these cases, a split dosing regimen may improve tolerability, particularly in patients who experience significant sedation or orthostatic hypotension with a single daily dose.
    3. Metabolic Side Effects and Compliance: In cases where metabolic side effects are of concern, or in patients who may not tolerate high single doses well, dividing doses could help with tolerability, potentially improving compliance and minimizing adverse effects like sedation or metabolic impact.
    4. Seizure Risk: High plasma peaks with a single large dose may theoretically increase the risk of seizures, especially in patients on higher doses of clozapine. Dividing doses is sometimes recommended as a preventive measure to maintain a more consistent blood level, although robust RCT data supporting this specific benefit is lacking.

    While RCT evidence specifically on clozapine dose-splitting remains limited, clinical judgment, patient tolerance, and monitoring of therapeutic blood levels play essential roles in tailoring dose regimens.

  • Raising the Bar: Should Buprenorphine Doses Be Higher to Combat Opioid Use Disorder?

    Raising the Bar: Should Buprenorphine Doses Be Higher to Combat Opioid Use Disorder?

    The study “Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization” explored how different buprenorphine doses affect emergency department (ED) and inpatient service use among individuals with opioid use disorder (OUD).

    1. Higher Doses Associated with Fewer Acute Care Visits: Patients receiving higher doses of buprenorphine (above 16 mg/day) had a longer time to ED or inpatient visits compared to those on lower doses (8-16 mg/day). Those on doses over 24 mg saw a significant reduction in the need for urgent care, particularly related to behavioral health crises.
    2. Implications for Fentanyl Users: The findings are particularly relevant for those using synthetic opioids like fentanyl, which often require higher doses of buprenorphine to manage withdrawal symptoms effectively. These higher doses may reduce acute care needs and improve overall treatment outcomes.
    3. Policy Considerations: The study highlights potential barriers, such as restrictive state laws or insurance limitations, that may prevent patients from accessing higher buprenorphine doses, which could limit effective treatment.

    These results suggest that modifying buprenorphine dosing guidelines could be beneficial, especially as the opioid crisis evolves with the prevalence of fentanyl​

    Link to article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824049

  • Rethinking Antipsychotics: Is It Time to Hit Pause for Schizophrenia Patients

    Rethinking Antipsychotics: Is It Time to Hit Pause for Schizophrenia Patients

    The article “Deprescribing Antipsychotics in Patients with Schizophrenia: Findings from a Specialized Clinic” emphasizes a growing interest in reducing or discontinuing antipsychotic medications in patients with schizophrenia, particularly those stable on long-term treatment. While continuous antipsychotic use is common to prevent relapse, concerns about long-term side effects, such as metabolic give us pause and rise concerns. 

    Key Points:

    1. Benefits of Deprescribing:
      • Reduction in side effects such as weight gain and metabolic syndrome.
      • Potential reversal of tardive dyskinesia.
      • Empowering patients by involving them in shared decision-making, improving adherence and satisfaction.
    2. Risks:
      • The primary risk is relapse, with studies indicating relapse rates between 20-60% after discontinuation.
      • Relapse can lead to hospitalization, job loss, and disrupted relationships.
    3. Strategies for Safe Deprescribing:
      • Individualized Tapering: Gradual reduction in dose is essential, tailored to the patient’s specific needs and history.
      • Relapse Prevention: Engaging support systems (family, mental health teams), monitoring for early signs of relapse, and incorporating psychosocial interventions.
      • Ethical Considerations: Balancing patient autonomy with the duty to minimize harm is a challenge. Encouraging patient participation respects autonomy while ensuring they are aware of risks.

    Future Directions:

    • More research is needed on long-term outcomes of deprescribing, particularly in identifying which patients are the best candidates for safe withdrawal.
    • Clinical guidelines should better integrate recovery-oriented approaches with deprescribing efforts to strike a balance between risk mitigation and promoting patient empowerment​

    link to the article: https://www.cambridge.org/core/journals/psychological-medicine/article/deprescribing-antipsychotics-in-patients-with-schizophrenia-findings-from-a-specialized-clinic/DA2F622FFA9D26A1F119F4F9BC11F2E3

  • Rational Polypharmacy and Evidence-Based Off-Label Prescribing: Navigating the Risks of Irrational Treatment

    Rational Polypharmacy and Evidence-Based Off-Label Prescribing: Navigating the Risks of Irrational Treatment

    Today’s post is more of a clinical reflection. I’ve been sharing a lot about research studies lately, but I want to pause and talk about polypharmacy in psychiatry and off-label prescribing. Have you ever been in a situation where a patient comes in, and as you review their medications, you see they’re taking a benzodiazepine for anxiety, an antidepressant for depression, a dopamine blocker for psychosis, and a mood stabilizer for mood swings? Maybe even a stimulant for ADHD is thrown in the mix. While I say that with some humor, in reality, this is a common scenario. As an educator, it’s crucial to discuss rational polypharmacy and evidence-based off-label prescribing, as well as the dangers of irrational, off-evidence prescribing.

    There are times when using more than one dopamine-blocking medication is necessary in the short term—I’ve done it myself to achieve short-term stabilization—but it would never be my long-term plan. Treatment resistance is another situation where off-label medication, if supported by evidence, could be beneficial. However, if none of these justifications apply and the patient isn’t improving, yet they’re on a potentially risky combination of medications, this is the moment to reconsider the diagnosis. It may sound surprising, but misdiagnosis in psychiatry happens often. If the patient isn’t getting better, it could be because you’re treating the wrong condition.

    It’s also possible that you’re addressing a disorder that isn’t the primary issue. For example, a patient being treated for ADHD may have attention and impulsivity problems, but these could actually stem from an underlying bipolar disorder. Since symptoms in psychiatry frequently overlap across multiple disorders, it’s essential to maintain a diagnostic hierarchy in your mind. Sorting out which disorder should be prioritized can often resolve other symptoms that might be masquerading as a different psychiatric condition.

    So, if treatment isn’t working and the medication list keeps growing, consider that there may have been a mistake in the diagnosis, or that the focus has been on the wrong condition. Often, many symptoms are driven by a more serious underlying disorder, like bipolar disorder.